Chi Sheng Chemical (4111) - Total Liabilities

Latest as of June 2025: NT$550.20 Million TWD ≈ $17.33 Million USD

Based on the latest financial reports, Chi Sheng Chemical (4111) has total liabilities worth NT$550.20 Million TWD (≈ $17.33 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See how liquid is Chi Sheng Chemical's working capital to evaluate short-term liquidity relative to the company's equity base.

Chi Sheng Chemical - Total Liabilities Trend (2017–2024)

This chart illustrates how Chi Sheng Chemical's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Chi Sheng Chemical (4111) total assets.

Chi Sheng Chemical Competitors by Total Liabilities

The table below lists competitors of Chi Sheng Chemical ranked by their total liabilities.

Company Country Total Liabilities
PP Properti Tbk PT
JK:PPRO
Indonesia Rp8.01 Trillion
Inspirato Inc
NASDAQ:ISPO
USA $362.26 Million
Regis Corporation Common Stock
NYSE:RGS
USA $399.61 Million
Datagate Bilgisayar Malzemeleri Ticaret AS
IS:DGATE
Turkey TL5.00 Billion
Integrated Logistics Bhd
KLSE:5614
Malaysia RM200.24 Million
Remed Co.Ltd
KQ:302550
Korea ₩15.50 Billion
Daewon Media Co. Ltd
KQ:048910
Korea ₩131.59 Billion
GP Global Power Ltd
TA:GPGB
Israel ILA118.52 Million

Liability Composition Analysis (2017–2024)

This chart breaks down Chi Sheng Chemical's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Chi Sheng Chemical balance sheet quality to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.84 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.43 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.30 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Chi Sheng Chemical's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Chi Sheng Chemical (2017–2024)

The table below shows the annual total liabilities of Chi Sheng Chemical from 2017 to 2024.

Year Total Liabilities Change
2024-12-31 NT$475.08 Million
≈ $14.97 Million
-13.15%
2023-12-31 NT$547.04 Million
≈ $17.23 Million
-5.42%
2022-12-31 NT$578.38 Million
≈ $18.22 Million
+3.46%
2021-12-31 NT$559.04 Million
≈ $17.61 Million
+36.04%
2020-12-31 NT$410.93 Million
≈ $12.95 Million
-8.73%
2019-12-31 NT$450.25 Million
≈ $14.19 Million
-1.74%
2018-12-31 NT$458.24 Million
≈ $14.44 Million
+6.97%
2017-12-31 NT$428.39 Million
≈ $13.50 Million
--

About Chi Sheng Chemical

TWO:4111 Taiwan Medical Instruments & Supplies
Market Cap
$54.10 Million
NT$1.72 Billion TWD
Market Cap Rank
#21688 Global
#1317 in Taiwan
Share Price
NT$28.70
Change (1 day)
+0.17%
52-Week Range
NT$28.55 - NT$30.85
All Time High
NT$36.05
About

Chi Sheng Pharma & Biotech Co., Ltd manufactures, processes, imports, exports, and sells western medicines, cosmetics, health food products, medical devices, and animal medicines in Taiwan and internationally. Its product portfolio includes antibiotics and chemotherapeutic agents; plasma substitutes and amino acid preparations; water nutrients and electrolyte preparations; vitamins; hepatotropic … Read more